Management of Ventricular Arrhythmias

Diagnosis and Risk Stratification

The American College of Cardiology recommends determining the presence of structural heart disease through 12-lead ECG, echocardiogram, assessment of electrolyte abnormalities, and review of QT-prolonging medications to guide treatment of ventricular arrhythmias 1
Risk factors that warrant more aggressive management include previous cardiac arrest, sustained ventricular tachycardia, syncope presumed due to ventricular arrhythmia, left ventricular ejection fraction ≤35%, and specific genetic disorders (LQTS, Brugada syndrome, CPVT) 1
Essential diagnostic steps include a 12-lead ECG, echocardiogram, and ambulatory monitoring, as recommended by the American College of Cardiology and the European Society of Cardiology 2, 3
Key historical findings, such as history of structural heart disease, wide complex tachycardia on previous ECGs, and syncope with exertion or emotional stress, are indicative of VT by the American College of Cardiology and the European Society of Cardiology 2, 3

The American College of Cardiology recommends beta blockers as first-line therapy for chronic ventricular arrhythmias in both structurally normal hearts and most cardiomyopathies, with additional therapies determined by underlying etiology, symptoms, and risk stratification 1
Beta blockers are particularly effective for VT related to myocardial ischemia, and are recommended for all patients with clinical diagnosis of ventricular arrhythmias 4
The European Society of Cardiology recommends beta-blocker therapy as first-line treatment for ventricular tachycardia (VT) in elderly patients, with careful consideration of underlying structural heart disease and comorbidities 5
Cardioselective beta-blockers are preferred in elderly patients to minimize adverse effects 5

The American Heart Association recommends considering antiarrhythmic medications if beta blockers/calcium channel blockers are ineffective or not tolerated, with a strength of evidence of IIa 1
The American College of Cardiology recommends considering catheter ablation for refractory cases, including outflow tract VT/PVCs, papillary muscle VT/PVCs, and interfascicular reentrant VT (verapamil-sensitive idiopathic LVT) 1
Amiodarone may be considered for persistent symptomatic VT, with caution and careful monitoring for adverse effects, particularly in elderly patients 5, 6
Procainamide is a first-choice agent for patients without severe heart failure or acute MI, with higher conversion rates than lidocaine 7

The American College of Cardiology recommends ICD implantation for secondary prevention (post cardiac arrest or sustained VT) if meaningful survival >1 year is expected, with a strength of evidence of I 1
The American Heart Association recommends continuing beta blockers to reduce ICD shocks, with a strength of evidence of IIa 8
Electrophysiology study may be considered for risk stratification if symptoms correlate with VT episodes, and catheter ablation is generally reserved for recurrent symptomatic VT refractory to medical therapy 5

The American College of Cardiology recommends ICD for patients with LVEF ≤30-35% despite optimal medical therapy, with a strength of evidence of I 4
The American Heart Association recommends considering wearable cardioverter-defibrillator in newly diagnosed heart failure while optimizing therapy, with a strength of evidence of IIb 8
ICD implantation is generally not recommended based solely on asymptomatic NSVT in elderly patients, unless left ventricular ejection fraction is ≤35% despite optimal medical therapy, or VT is hemodynamically unstable or symptomatic 5, 6

The American College of Cardiology recommends beta blockers for all patients with clinical diagnosis of long QT syndrome, with additional therapies for high-risk patients (QTc >500ms, recurrent syncope) including left cardiac sympathetic denervation and ICD 1
The American Heart Association recommends avoiding QT-prolonging medications in patients with long QT syndrome, with a strength of evidence of III 1
The American College of Cardiology recommends beta blockers for all patients with clinical diagnosis of Brugada syndrome, with additional therapies for recurrent events including combination therapy with flecainide, left cardiac sympathetic denervation, and/or ICD 1
The American Heart Association recommends ICD for symptomatic patients with spontaneous type 1 pattern and cardiac arrest/VT/syncope, with a strength of evidence of IIa 1

The American Heart Association recommends avoiding intensive exercise in patients with catecholaminergic polymorphic ventricular tachycardia, with a strength of evidence of III 8
Regular follow-up with cardiac evaluation every 3-6 months, and monitoring for medication side effects, particularly with beta-blockers and amiodarone, is necessary for optimal management of VT 5, 6
Continuous ECG monitoring and blood pressure monitoring are essential, with central venous access preferred for amiodarone concentrations >2 mg/mL 9

VT storm is a life-threatening condition that requires immediate and aggressive management, with correction of reversible causes such as electrolyte abnormalities, acid-base disturbances, myocardial ischemia, and drug toxicity, as recommended by the European Heart Society and the American College of Cardiology 3, 5
Correct electrolyte abnormalities by maintaining potassium >4.0 mEq/L and magnesium >2.0 mg/dL, and address underlying causes such as urgent coronary revascularization if evidence of ischemia 7
Consider electrical cardioversion if pharmacological management fails 9, 7
For drug-refractory polymorphic VT, consider β-adrenoceptor blockade, intra-aortic balloon pumping, and emergency PTCA/CABG surgery 9

Elderly patients should generally receive the same treatment approaches as younger individuals, but with dose adjustments, and medication dosing should be started lower and titrated more slowly due to altered pharmacokinetics 6
The American College of Cardiology recommends considering comorbidities that may affect treatment choices, and avoiding ICD implantation if life expectancy is less than 1 year due to major comorbidities 6
Patients with clinical history findings suggestive of ventricular tachycardia (VT) should be immediately referred to a cardiac arrhythmia specialist for comprehensive evaluation and management due to the significant risk of morbidity and mortality, as recommended by the European Society of Cardiology and the American College of Cardiology 3, 2